ストックスクリーナーアプリを入手
3.175
2.16%
-0.065
前日終値:
$3.24
開ける：
$3.24
24時間の取引高:
377.33K
Relative Volume:
0.23
時価総額：
$344.00M
収益：
$27.08M
当期純損益:
$-37.00M
株価収益率:
-6.1058
EPS:
-0.52
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
-0.63%
1か月 パフォーマンス:
-29.56%
6か月 パフォーマンス:
+76.11%
1年 パフォーマンス:
+41.52%
1日の値動き範囲:
$3.145
$3.31
1週間の範囲:
$3.11
$3.38
52週間の値動き範囲:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.175 | 351.04M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.57 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.13 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
832.11 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.50 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
365.65 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Piper Sandler | Overweight |
| 2025-05-28 | 開始されました | Wedbush | Outperform |
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Aclaris Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Market Rankings: Whats the beta of Seacoast Banking Corporation of Florida stockJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Will Aclaris Therapeutics Inc. stock recover faster than peersWeekly Market Report & Community Driven Trade Alerts - mfd.ru
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 - MarketBeat
Aclaris at Guggenheim Summit: Strategic Biotech Developments By Investing.com - Investing.com Nigeria
Aclaris at Guggenheim Summit: Strategic Biotech Developments - Investing.com
What’s the beta of Aclaris Therapeutics Inc. stock2025 Fundamental Recap & Long-Term Investment Growth Plans - mfd.ru
Atopic Dermatitis Market to hit $31.68 billion by 2033 | Major - openPR.com
February 2026's Promising Penny Stocks To Consider - Yahoo Finance
Aclaris lines up February spotlight at major biotech investor conferences - MSN
Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences - MyChesCo
Aclaris Therapeutics to Participate in Two February Healthcare Conferences - Investing News Network
Experimental hair-loss drug sparks rapid regrowth in severe alopecia study - MSN
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - simplywall.st
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study - MyChesCo
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Downgrade Watch: Whats the fair value of Aclaris Therapeutics Inc stock2025 Market Sentiment & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating - Investing.com Canada
Looking Into Aclaris Therapeutics Inc's Recent Short Interest - Benzinga
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris ATI-2138 Shows Superior Efficacy in Hair Loss Treatment - intellectia.ai
Aclaris Therapeutics' (ACRS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results - Investing.com Canada
Aclaris reports positive preclinical results for hair loss drug By Investing.com - Investing.com Canada
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
Aclaris reports positive preclinical results for hair loss drug - Investing.com
Aclaris Therapeutics' ATI-2138 Shows Superior Efficacy Against Ritlecitinib in Alopecia Universalis Model - Quiver Quantitative
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 - GlobeNewswire
Aclaris Therapeutics (NASDAQ:ACRS) versus Vivani Medical (NASDAQ:VANI) Head to Head Review - Defense World
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st
Market Rankings: What is Aclaris Therapeutics Incs book value per shareProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) nasdaq top 100 Clinical Pipeline - Kalkine Media
Aclaris pushes new antibody into skin disease trial, eyes asthma next - MSN
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment - MSN
ACRS: Analyst Maintains Buy Rating and $16 Price Target | ACRS S - GuruFocus
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 41% Price Jump - 富途牛牛
Income Plays: What are the future prospects of Aclaris Therapeutics IncWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next - MyChesCo
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsMarket Activity Report & High Accuracy Investment Entry Signals - bollywoodhelpline.com
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
0.46%
1.00%
大文字化:
|
ボリューム (24 時間):